Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)

European Journal of Cancer

Volumn 42, Issue 18, 2006, Pages 3178-3185

  Beex, L ^a   Rose, C ^b   Mouridsen, H ^c   Jassem, J ^d   Nooij, M ^e   Estape, J ^f   Paridaens, R ^g   Piccart, M ^h   Gorlia, T ⁱ   Lardenoije, S ^a   Baila, L ⁱ  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c FINSEN LABORATORY   (Denmark)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ EORTC DATA CENTER   (Belgium)

Author keywords

Advanced breast cancer; Alternated endocrine therapy; Intermittent endocrine therapy; Medroxyprogesterone acetate; Randomised study; Tamoxifen

Indexed keywords

MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; TAMOXIFEN;

EID: 33845224929     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.08.020     Document Type: Article

References (36)

1. Sluyser M., and van Nier R. Estrogen receptor content and hormone responsive growth of mammary tumours. Cancer Res 34 (1974) 3253-3275
2. Kim U., and Depowski M. Progression from hormone dependence to autonomy in mammary tumors as in vivo manifestation of sequential clonal selection. Cancer Res 35 (1975) 2068-2077
3. Noble R. Hormonal control of growth and progression in tumours of Nb rats and a theory of action. Cancer Res 37 (1977) 82-94
4. Kitamura Y., Okamoto S., Uchida N., Yamaguchi K., and Matsumoto K. Effect of androgen depletion on growth and androgen dependency of Shionogi carcinoma 115. Cancer Res 38 (1978) 4711-4716
5. Noble R., and Hoover L. Classification of transplantation tumors in Nb rats controlled by estrogen from dormancy to autonomy. Cancer Res 35 (1975) 2935-2941
6. Bruchovsky N., Rennie P., van Doorn E., and Noble L. Pathological growth of androgen sensitive tissues resulting from latent actions of steroid hormones. J Toxicol Environ Health 4 (1978) 391-408
7. Stoll B.A. Rechallenging breast cancer with tamoxifen therapy. Clin Oncol 9 (1983) 347-351
8. Klotz L., Herr H., Morse M., and Whitmore W. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58 (1986) 2546-2550
9. Rose C, Mouridsen HT, Engelsman E, Sylvester R, Rotmensz N. Oral medroxyprogesterone acetate treatment of postmenopausal patients with advanced breast cancer. An evaluation of the dose-response relationship at two dose levels. A phase III trial (EORTC Breast Cancer Group: trial 10802). In: Proceedings of the 4th EORTC Breast Cancer Working Conference, London; 1987 [abstr.1.11].
10. Fabian C., Sternson L., El-Seraf M., Cain L., and Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48 (1981) 876-882
11. WHO. handbook for reporting results of cancer treatment (1979), WHO, Geneva
12. Rose C., and Mouridsen H. Treatment of breast cancer with tamoxifen. Recent results in cancer research 91 (1984) 230-242
13. Miller B., Miller F., Leith J., and Heppner G. Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res 40 (1980) 3977-3981
14. Isaacs J.T. The biology of hormone refractory prostate cancer. Urol Clin North America 26 (1999) 263-273
15. Poste G., Doll J., and Fidler I. Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells. Proc Natl Acad Sci USA 78 (1981) 6226-6230
16. Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., Lawson D., et al. Effects of androgen withdrawal on stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
17. Akakura K., Bruchovsky N., Rennie P., et al. Effects of intermittent androgen supression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shinonogi carcinoma. J Ster Biochem Molec Biol 59 (1996) 501-511
18. Osborne C.K., and Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23 (2005) 1616-1622
19. Cui X., Schiff R., Arpino G., Osborne C.K., and Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23 (2005) 7721-7735
20. Gee JMW, Howell A, Gullick WJ, et al. Consensus statement. Therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. In: Proceedings of the Tenovus/AstraZeneca workshop, Endocrine Related Cancer, vol. 12; 2005. p. S1-7.
21. Robertson J.F., Come S.E., Jones S.E., et al. Endocrine options for advanced breast cancer-the role of fulvestrant. Eur J Cancer 41 (2005) 346-356
22. Rose C., Kamby C., Mouridsen H.T., et al. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomised trial of tamoxifen vs tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Research Treat 7 Suppl. (1986) S45-S50
23. Rose C., Kamby C., Mouridsen H.T., et al. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomised trial of tamoxifen vs tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Res Treat 61 (2000) 103-110
24. Ingle J., Green S., Ahmann D., et al. Randomised trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 6 (1986) 958-964
25. Klijn J., Blamey R., Boccardo F., Tominaga T., Duchateau L., Sylvester R., et al. Combined tamoxifen and luteinising hormone releasing hormone (LH-RH) in premenopausal advanced breast cancer: a meta analysis of four randomised trials. J Clin Oncol 19 (2001) 343-353
26. Prostate cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
27. Muss H., Smith R., and Cooper M.R. Tamoxifen rechallenge; response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol 5 (1987) 1556-1558
28. Bhandari M.S., Crook J., and Husseib M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 (2005) 8212-8218
29. Lane T., Ansell W., Farrugia D., et al. Long term outcomes in patients with prostatic cancer managed with intermittent androgen suppression. Urol Int 73 (2004) 117-122
30. De Leval J., Boca P., Yousef E., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-nai{dotless}̈ve prostate cancer: results of a prospective randomised multicenter trial. Clin Prostate Cancer 3 (2002) 163-171
31. Coombes R., Hall E., Gibson L., et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 350 (2004) 1081-1092
32. Goss P., Ingle J., Martino S., et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Eng J Med 349 (2003) 1793-1802
33. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years'adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 431-433
34. Gundersen S., Kvinnsland S., Lundgren S., et al. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 17 (1990) 45-50
35. Beltrán M., Alonso M.C., Ojeda M.B., et al. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients. Ann Oncol 2 (1991) 495-499
36. Raemaekers J., Beex L., Koenders A., et al. Concordance and disconcordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival. Eur J Cancer 20 (1984) 1011-1018